This article is more than 5 years old. Information may no longer be current.

NovaBone receives FDA approval for MacroFORM MIS Delivery System

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaBone Products has announced the FDA approval of its NovaBone MacroFORM MIS Delivery System. 

Designed for use in minimally invasive orthopedic procedures, the MacroFORM MIS Delivery System allows direct delivery of bone marrow aspirate to a graft in a closed cannula. According to a company release, the system will better enable surgeons to deliver bone grafting material to surgical locations not easily accessible.

“The MacroFORM MIS Delivery System builds off the commercial success of the intuitively designed collagen devices we have launched over the past several months,” Dennis McBride, vice president of sales and marketing for NovaBone, stated in the release.

Reference: www.novabone.com